What BPC-157 is
BPC-157 is a 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice. The "BPC" stands for Body Protection Compound. It was first isolated and characterized at the University of Zagreb in the early 1990s and has been studied almost exclusively in animal models since.
It is not FDA-approved. It is sold as a research-use-only compound. Its exact mechanism of action remains incompletely characterized, though hypothesized to involve angiogenesis, nitric oxide signaling, growth factor expression, and modulation of the dopaminergic and serotonergic systems.
What the animal data shows
This is where most of the BPC-157 reputation comes from. In animal studies (rat, rabbit, mouse), BPC-157 has demonstrated:
- Accelerated tendon-to-bone healing after surgical transection (multiple replicated studies, Achilles and rotator cuff models)
- Faster ligament healing in medial collateral ligament transection models
- GI tract protective effects including ulcer healing and inflammatory bowel models
- Reduction in NSAID-induced gastric damage
- Wound healing acceleration including burns and excisions
- Some neuroprotective effects in stroke and TBI models
The breadth of effects is genuinely impressive — and is also the source of the skepticism. A compound that helps with everything is suspicious. Either the mechanism is unusually upstream (which is plausible for a natural protective compound), or there's a publication bias problem in the literature.
The University of Zagreb group has produced the bulk of the published BPC-157 work. Independent replication outside that group is real but more limited.
What the human data shows
Almost nothing. There are zero high-quality randomized controlled trials in humans. The published human work is limited to small case series, anecdotal reports, and observational data. The popular consumer use is essentially a giant uncontrolled experiment.
That doesn't mean it doesn't work. It means we don't have rigorous human evidence to confirm efficacy or characterize safety beyond what users self-report.
What users report
The dominant consumer use is for tendon and joint pain — usually golfer's elbow, tennis elbow, patellar tendinitis, rotator cuff strain. Anecdotal reports cluster around:
- Subjective relief between week 2-4 at standard sub-q doses
- Clearer functional improvement by week 6-8
- Effects often persist after discontinuation — unlike NSAIDs which mask pain transiently
- GI / gut healing effects less consistently reported but cited in users with IBS or NSAID damage
The "near the injury" injection question (subcutaneous near the injured tissue versus general subcutaneous) is debated. The animal evidence does not strongly support local-only efficacy — systemic dosing produces effects too — but local injection remains the popular pattern.
The documented protocol on Pepdex
Per the BPC-157 entry:
- Dose range: 200 to 500 mcg per day, sub-q
- Duration: 4-8 week cycles common, with 2-4 week breaks
- Stack pairing: TB-500 (often combined for tendon work)
- Side effects documented: localized injection-site reactions, transient mild dizziness, rare reports of mild nausea
- Contraindications: active cancer (theoretical concern given angiogenic effects), pregnancy, breastfeeding
Educational only. Personal dosing decisions are between you and a qualified provider.
What we don't know
- Long-term safety in humans (no data past ~12 months continuous use)
- Cancer signal (theoretical concern from angiogenesis pathway, not yet seen in cohort observation)
- Optimal dose for any specific indication in humans (extrapolated from animal models)
- Whether oral BPC-157 is meaningfully bioavailable (mixed evidence)
- Quality variance across consumer-market vials (significant, based on third-party COA testing)
What this means for a user evaluating BPC-157
The animal data is genuinely strong for tissue and tendon healing. The human data is mostly absent. The user-reported track record is positive but unverifiable.
If you are running it, the variables most under your control are: 1. Source quality — see the COA literacy guide and scam vendor spotting. 2. Staying inside the documented dose range — escalating doesn't have a known efficacy benefit and widens unknowns. 3. Cycling appropriately — not running continuously beyond 8 weeks without breaks. 4. Tracking response objectively — pain scale, range of motion, function. If 6 weeks in there's no signal, the compound probably isn't the bottleneck for your specific injury.
The full BPC-157 page on Pepdex is at /peptides/bpc-157 with full breakdown of mechanism, dose protocols, side effects, common mistakes, and bloodwork recommendations.
Where to go next
- The TB-500 page — commonly stacked for tendon work
- Healing peptides category — full list
- Are peptides safe? — the safety landscape generally
Want the full breakdown on every peptide?
$7.99/mo unlocks the AI Coach, Personal Stack, and complete per-peptide deep sections.
Upgrade to Pepdex →